吉非替尼治疗肺鳞癌的效果及对患者CRP水平的影响

Effect of gefitinib in the treatment of lung squamous cell carcinoma and its effect on CRP level

目的探究吉非替尼治疗肺鳞癌的效果及对患者CRP水平的影响。方法将我院2017年2月至2018年12月收治的78例肺鳞癌患者按照随机数字表法分为观察组(吉非替尼治疗)与对照组(常规治疗),每组39例。比较两组的治疗效果。结果治疗后,两组CRP水平均降低,且观察组低于对照组(P<0.05)。观察组的治疗总有效率高于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论吉非替尼治疗肺鳞癌能够促进患者CRP水平改善,且不增加不良反应,效果显著,值得推广应用。

Objective To investigate the effect of gefitinib in the treatment of lung squamous cell carcinoma and its effect on C-reactive protein(CRP)level.Methods From February 2017 to December 2018,78 patients with lung squamous cell carcinoma were randomly divided into observation group(gefitinib treatment)and control group(routine treatment),with 39 cases in each group.The therapeutic effects of the two groups were compared.Results After treatment,CRP levels in both groups decreased,and that in the observation group was lower than the control group(P<0.05).The total effective rate of treatment in the observation group was higher than that of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Gefitinib in the treatment of lung squamous cell carcinoma can promote the improvement of CRP level without increasing adverse reactions.It has a remarkable effect,which is worthy of popularization and application.